Open Access
Combining TMS and Ketamine for Treatment-Resistant Depression: Clinical Rationale, Current Evidence, and Practical Guidance
Focus · 2026-07 · 24 (3) · 326-330
DOI: 10.1176/appi.focus.20260014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Focus, 2026-07. Verfasst von Ian A Cook. Beteiligte Einrichtung: Los Angeles TMS Institute, Los Angeles. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Depression
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Nonpharmacologic Somatic TreatmentdepressionketaminerTMS
Autor:innen und Institutionen
- Los Angeles TMS Institute, Los Angeles.
Zitieren
APA
Cook, I. A. (2026). Combining TMS and Ketamine for Treatment-Resistant Depression: Clinical Rationale, Current Evidence, and Practical Guidance. Focus, 24(3), 326-330. https://doi.org/10.1176/appi.focus.20260014
Vancouver
Cook IA. Combining TMS and Ketamine for Treatment-Resistant Depression: Clinical Rationale, Current Evidence, and Practical Guidance. Focus. 2026;24(3):326-330. doi:10.1176/appi.focus.20260014
BibTeX
@article{Cook2026,
author = {Cook, Ian A},
title = {Combining TMS and Ketamine for Treatment-Resistant Depression: Clinical Rationale, Current Evidence, and Practical Guidance},
journal = {Focus},
year = {2026},
volume = {24},
number = {3},
pages = {326--330},
doi = {10.1176/appi.focus.20260014}
}
EUVIMED